abiraterone,olaparib,abiraterone
astrazeneca,merck
['abira', 'crpc', 'pcsm', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'olaparib', 'propel', 'abiraterone']
propel results unveiled at #gu23: first-line olaparib/abiraterone showed a trend toward os improvement by ~7 months compared with soc abiraterone alone in men with mcrpc. #ascodailynews #pcsm
Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.